Section 232 tariff relief for orphan drugs: Who may qualify
Executive summary: How section 232 tariff relief may affect orphan drugs and life sciences
Life sciences companies may have new opportunities to reduce section 232 tariff exposure on orphan drugs, associated pharmaceutical ingredients and certain development-stage imports.
New U.S. Department of Commerce guidance defines which specialty pharmaceutical products may qualify for a 0% tariff rate and identifies pathways based on product eligibility, country of origin and urgent U.S. health needs. The guidance also addresses investigational drugs and certain products imported for clinical trials, research and development, and other noncommercial uses.
For orphan drug manufacturers and importers, the implications can extend beyond finished products to materials used throughout the manufacturing supply chain. Understanding how product status, origin and intended use intersect with the new rules can reveal where tariff relief may be available and where exposure remains.
How orphan drugs may qualify for 0% section 232 pharmaceutical tariff relief
Life sciences companies importing orphan drugs and associated pharmaceutical ingredients may qualify for a 0% section 232 tariff rate under new Commerce Department guidance.
A qualifying orphan drug that originates in a jurisdiction identified by the Commerce Department may receive the 0% tariff treatment without an urgent U.S. health need determination. When that jurisdiction-based pathway is unavailable, an urgent U.S. health need may provide a separate route to tariff relief.
Determining eligibility begins with the product itself. The Commerce Department defines the orphan drug category as a drug or biological product designated for one or more rare diseases or conditions “for which all approved indications … are for one or more such rare diseases or conditions.”
Determining whether an orphan drug qualifies
The following three questions can help companies assess whether an orphan drug may qualify for 0% section 232 tariff treatment:
An orphan drug designation alone does not necessarily answer the eligibility question. Under the Commerce Department’s definition, a drug or biological product must be designated for one or more rare diseases or conditions, and all its approved or licensed indications must be for one or more such rare diseases or conditions.
That distinction can matter when a product has multiple approved indications. Understanding the regulatory status of each indication can help a company determine whether a product fits the orphan drug category used for section 232 tariff purposes.
The guidance’s inclusion of investigational drugs also makes regulatory status relevant for products that have not yet reached commercialization.
Specialty pharmaceutical products and associated pharmaceutical ingredients may receive 0% section 232 tariff treatment when they are products of an eligible jurisdiction.
The Commerce Department currently identifies the following jurisdictions as eligible, noting changes to the list may be published in a future notice:
- Argentina
- Bangladesh
- Cambodia
- Ecuador
- El Salvador
- European Union
- Guatemala
- India
- Indonesia
- Japan
- Jordan
- Malaysia
- North Macedonia
- Republic of Korea
- Switzerland and Liechtenstein
- Taiwan
- Thailand
- United Kingdom
- Vietnam
If a qualifying orphan drug originates in an eligible jurisdiction, it may receive 0% section 232 tariff treatment without an urgent U.S. health need determination.
When a product cannot qualify through the eligible-jurisdiction pathway, a company may request 0% section 232 tariff treatment based on an urgent U.S. health need. This is a separate pathway, not an additional requirement for qualifying products from eligible jurisdictions.
The Commerce Department, in consultation with the U.S. Trade Representative and U.S. Department of Health and Human Services, makes an individual, fact-specific and company-specific determination for each request.
The guidance calls for information about the product, its tariff classification, country of origin and export, importer and manufacturer. A company’s rationale may include the disease the product treats, the availability or lack of alternative therapies, the number of U.S. patients who use the product and whether it is available in other jurisdictions.
The urgent U.S. health need pathway may be particularly relevant for orphan therapies when factors affecting patient access include:
- Small and medically vulnerable patient populations
- Limited or unavailable alternative therapies
- Highly specialized supply chains
- The potential for supply interruptions to affect access to treatment
Understanding those circumstances, together with the information identified by the Commerce Department, can help a company evaluate whether the urgent U.S. health need pathway may be relevant when jurisdiction-based treatment is unavailable.
Section 232 tariff relief for development-stage products
The guidance creates a new Harmonized Tariff Schedule of the United States heading for pharmaceutical articles and associated ingredients that are solely for use in clinical trials, research and development, or other noncommercial applications. Imports meeting the requirements of that provision receive an additional 0% section 232 tariff rate.
Depending on the circumstances, development-stage imports may have other potential tariff-relief pathways, including the U.S. tariff provision for qualifying prototypes.
The provision may be particularly relevant for biotech and other life sciences companies that import materials for clinical trials, research and development, and other activities well before commercialization. Depending on a company’s development and manufacturing processes, those imports can include clinical-trial supplies and materials used in producing investigational therapies.
For companies importing products before commercialization, intended use can therefore be an important factor in identifying where the separate 0% section 232 tariff treatment may apply.
How pharmaceutical ingredients affect section 232 tariff treatment
The section 232 framework extends beyond finished pharmaceutical products. The Commerce Department defines “pharmaceutical articles” to include finished pharmaceutical products, active pharmaceutical ingredients (APIs) and key starting materials for active pharmaceutical ingredients. Inactive ingredients and excipients are excluded from that definition.
For life sciences companies, understanding the treatment of materials throughout the supply chain may require looking beyond finished products. Depending on the company’s products and manufacturing processes, those materials can include:
- Drug substances
- Biological materials
- Specialized intermediates
- Cell and gene therapy manufacturing inputs
Looking at more than the finished product can help companies identify potential section 232 tariff treatment elsewhere in the manufacturing supply chain. Understanding how those materials are classified and used can clarify where pharmaceutical tariffs may apply and where 0% tariff treatment may be available.
Evaluating potential section 232 tariff relief
Companies can focus on several areas when evaluating how the new guidance may affect their section 232 tariff exposure:
Assessing section 232 pharmaceutical tariff exposure
For orphan drug manufacturers and other life sciences companies, determining whether an imported product qualifies for favorable treatment may be as important as understanding the applicable tariff rate itself. The analysis can depend on the product, its origin and, in some cases, its intended use or an urgent U.S. health need.
Applying those factors across a company’s product pipeline can help identify where tariff relief may be available and where section 232 exposure remains.
Related insights
- /insights/services/business-tax/tariffs-swiss-origin-generic-pharmaceuticals
- /insights/industries/life-sciences/fda-complete-response-letters-outsourcing-quality-challenges
- /insights/industries/life-sciences/common-pitfalls-avoid-successful-biopharma-launch